Xiang H, Mortenson GP, Lang SB, Jakkaraju S, Chirala A, Zhu Y, Jia M, Wen J, Chen Y, Baghela A, Chen YC, Sze MA, Hegde LG, Zhang-Hoover J, Willingham A, Handa M, Chi A, Baltus GA, Kamath RV, Levesque M, Vollmann EH (2026) uPAR-targeting cytotoxic antibody–drug conjugates selectively deplete proinflammatory myeloid cells for autoimmune indications. Cells 15(9):803. doi: 10.3390/cells15090803
Objective: To explore uPAR as a cell-surface marker to target and eliminate proinflammatory monocytes and macrophages using antibody–drug conjugates (ADCs).
Summary: Using recent scRNA-seq findings from RA patients, the authors identified the urokinase plasminogen activator receptor (uPAR), encoded by PLAUR, as a highly expressed cell surface marker on an inflammation-associated IL1B+ proinflammatory myeloid subset. an anti-uPAR mAb conjugated with monomethyl auristatin F (MMAF) was employed to demonstrate selective depletion of uPARhigh-expressing macrophages in a myeloid-rich rodent model.
Usage: Fab-ZAP rat (IT-55) was used to test the internalization capacity of anti-mouse uPAR mAbs. Saporin and Fab-IgG-ZAP were used as control.
Related Products: Fab-ZAP rat (Cat. #IT-55), Fab IgG-SAP (Cat. #IT-67), Saporin (Cat. #PR-01)